¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"edge plasma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè
  • plasma exchange
    Ç÷À屳ȯ(¼ú)
  • plasma expander
    Ç÷ÀåÁõ·®Á¦
  • plasma hemoglobin
    Ç÷ÀåÇ÷»ö¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
  • plasma membrane
    ÇüÁú¸·
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma hemoglobin
    Ç÷ÀåÇ÷¾×¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma membrane
    ÇüÁú¸·
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma cross matching
    (¢¡cross matching) Ç÷Àå±³Â÷½ÃÇè
  • plasma
    Ç÷Àå, ¿øÇüÁú, ¼¼Æ÷Áú
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma substitute
    Ç÷Àå´ëÄ¡Á¦
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma iron pool
    Ç÷ÀåöÀúÀå°í
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà).
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷ÀÌȥȭÁõ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ(û¡òõá¬øàòðü´), ÇüÁú¼¼Æ÷Àå¾Ö(¡­î¡äô), ÇüÁú¼¼Æ÷ÀÌȥȭÁõ(¡­ì¶ûèûúñø)
  • plasma cell gingivostomatitis
    ÇüÁú¼¼Æ÷ Ä¡Àº ±¸³»¿°
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´(û¡òõá¬øààõ ÛÜúìÜ»)
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷¼ºÀ¯¹æ¿°(û¡òõá¬øààõêáÛ®æú)
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷ °ñ¼öÁ¾
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾(û¡òõá¬øàÍéâÐðþ)
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼º Æó·Å.
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼ºÆó·Å(û¡òõá¬øààõøËæú)
  • plasma cell tumor
    ÇüÁú¼¼Æ÷Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • edge enhancing algorithm
    º¯¿¬ Áõ°­ ¿¬»ê
  • edge ringing artifact
    º¯¿¬ ¿ï¸² Àΰø¹°
  • edge sealing
    ´ÜºÀ(Ӯܿ).
  • edge sign
    º¯¿¬ ¡ÈÄ
  • edge sign
    °¡ÀåÀÚ¸® ¡ÈÄ (ó£ý¦)
  • edge-strength
    ¿¬´Ü°­µµ(æÞӮ˭öô).
  • free edge
    ÀÚÀ¯ º¯¿¬ºÎ
  • incisal edge
    Àý´Ü(ôîÓ®).
  • knife edge
    Ä®³¯.
  • leading edge
    ¼±µµ¿¬.
  • mesial cutting edge
    ±Ù½ÉÀý´Ü¿¬(¡­ôîÓ¨æÞ).
  • occlusal edge
    ±³ÇÕ¿¬(ÎáùêæÞ).
  • tibial edge
    °æ°ñ¸ª(ÌëÍé×Ò).
  • wound edge
    ⿬(⿬).
  • wound edge
    ⿬(óïæÞ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma thromboplastin component
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ¼ººÐ(à÷ÝÂ)
  • plasma transferrin
    Ç÷Àå(úìíì) Æ®¶õ½ºÆä¸°
  • plasma transglutaminase
    Ç÷Àå(úìíì) Æ®¶õ½º±Û·çŸ¹Ì³×À̽º
  • separated plasma
    ºÐ¸®Ç÷Àå(ÝÂ×îúìíì)
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • true plasma
    ¼øÇ÷Àå(âíúìíì)
  • whole plasma
    ÀüÇ÷Àå(îïúìíì)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
PG paregoric; parotid gland; pentagastrin; pepsinogen; peptidoglycan; Pharmacopoeia Germanica; phosphat...
PP diphosphate group; emphysema [pink puffers]; near point of accommodation [Lat. punctum proximum]; pa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
APC Argon Plasma Coagulation
BPA Bovine plasma albumin
D/P Dialysate to plasma
D/P Dialysate-to-plasma ratio
D/P Dialysate/plasma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood plasma substitute
    ´ë¿ë Ç÷Àå
  • citrated normal human plasma
    Á¤»óÀÎ ±¸¿¬»ê¿° ÷°¡ Ç÷Àå
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • pathologic plasma protein
    º´Àû Ç÷Àå ´Ü¹é
  • plasma cell
    ÇüÁú±¸, Ç÷Àå ¼¼Æ÷, ÇüÁú ¼¼Æ÷
    1. Ç×ü¸¦ ºÐºñÇÒ ¼ö ÀÖ´Â ¼¼Æ÷. 2. ¸¸¼º ¿°ÁõÀ̳ª ƯÁ¤ Áúȯ »óÅÂ, ¶Ç´Â Á¾¾ç¿¡¼­ ³ªÅ¸³ª´Â ¼¼Æ÷·Î ¼øÈ¯ Ç÷¾×¿¡ Á¤»óÀûÀ¸·Î ³ªÅ¸³ªÁö´Â ¾Ê´Â´Ù. Å©±â´Â Àӯı¸º¸´Ù Å©¸ç, È£¿°±â¼ºÀÇ ¿°»öÁúÀ» °¡Áö´Â ÇÙÀÌ ¼¼Æ÷ÀÇ Á߽ɿ¡¼­ ¹þ¾î³ª ½Ã°èÀÇ ¼ýÀÚÆÇÀÇ ¼ýÀÚµéó·³ º¯¿¬¿¡ À§Ä¡Çϰí ÀÖ´Ù. ÀÌ ¼¼Æ÷ÀÇ ±â¿ø¿¡ °üÇØ¼­´Â
  • plasma cell dyscrasia
    Ç÷Àå ¼¼Æ÷ ÀÌ»ó
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • plasma cloud
    Çö󽺸¶ ±¸¸§
  • plasma cortisol
    Ç÷Àå ÄÚÆ¼Á¹
  • plasma extravasation
    Ç÷Àå À¯Ãâ, Ç÷Àå ÀÏÇ÷
  • plasma formation
    Çö󽺸¶ Çü¼º
  • plasma hemoglobin
    Ç÷Àå Çì¸ð±Û·Îºó, Ç÷Àå Ç÷¾×¼Ò
  • plasma membrane
    ¿øÇüÁú ¸·, ¼¼Æ÷ ÇüÁú¸·
    ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº ¸·. µÎ²²´Â 5¡­25 ¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ÀÌ ¸·Àº ¿øÇüÁú Ç¥¸é, Áï ¸Å¾×°úÀÇ °è¸é¿¡ Çü¼ºµÈ ÈíÂø¸· ¶Ç´Â ħÀü¸·À¸·Î »ý°¢µÈ´Ù. ¿øÇüÁú ¸·ÀÇ ºÐÀÚ ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀÇ Ç¥¸é Ȱ¼º ¹°Áú ºÐÀÚ°¡ 2ºÐÀÚ ÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿­µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚ ÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼­ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï, ¸í, ¾ÏÀÇ 3Ãþ
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
bean-shaped plasma <radiobiology> A toroidal plasma indented on the inboard side (the side with the donut hole), that results in additional stability to ballooning modes. Moderate indentation may provide access to the second-stability region (high beta).
(13 Nov 1997)
blood plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
blood plasma fractions Portions of the blood plasma as separated by electrophoresis or other technique.
(05 Mar 2000)
rapid plasma reagin <investigation> The rapid plasma reagin test is similar to the VDRL test for diagnosing syphilis. This blood test is designed to detect an antibody substance in the bloodstream when syphilis infection is present. Early syphilis infections may be RPR negative.
See: VDRL
(17 Dec 1997)
rapid plasma reagin test A group of serologic test's for syphilis in which unheated serum or plasma is reacted with a standard test antigen containing charcoal particles; positive test's yield a flocculation. A modification, called the RPR (circle) card test, is widely used as a screening test.
Synonym: RPR test.
(05 Mar 2000)
renal plasma flow <physiology> The amount of plasma that perfuses the kidneys per unit time, approximately 10% greater than effective renal plasma flow.
It should be differentiated from the renal blood flow which refers to the total volume of blood flowing through the renal vasculature, while the renal plasma flow refers to the rate of plasma flow.
(12 Dec 1998)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
granuloma, plasma cell A slow-growing benign pseudotumour in which plasma cells greatly outnumber the inflammatory cells.
(12 Dec 1998)
granuloma, plasma cell, orbital A distinctive, chronic inflammatory reaction in the orbital tissues of the eye, of unknown aetiology, that may closely resemble a neoplasm and often becomes bilateral. Symptoms include exophthalmos and congestion of the lids with oedema. When limitation of ocular motility also occurs, it is sometimes called orbital myositis.
(12 Dec 1998)
granuloma, plasma cell, pulmonary A pseudotumour of the lung composed of inflammatory cells and showing complete maturity of fibroblastic components with a striking lack of mitosis. It is also called postinflammatory pseudotumour and pseudoneoplastic pneumonitis. (berardi, r.s. Et al. Inflammatory pseudotumours of the lung. Surg gynecol obstet 156:89-96, jan 83)
(12 Dec 1998)
collisionless plasma model <radiobiology> Model of a plasma in which the density is so low, or the temperature so high, that close binary (two-body) collisions have practically no significance (on certain timescales) because the time scales of interest are shorter than the collision time. Yields valid physical results for timescales much shorter than the average collision time in a real plasma.
(09 Oct 1997)
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
plasma cell <haematology> A terminally differentiated antibody forming and usually antibody secreting, cell of the B-cell lineage.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á